Tirzepatide emerges a groundbreaking pharmaceutical agent for individuals struggling type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, resulting in synergistic effects on blood sugar control. By augmenting insulin secretion while simultaneously r